Evotec SE

  • WKN: 566480
  • ISIN: DE0005664809
  • Land: Germany

Nachricht vom 06.09.2019 | 10:59

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: Evotec SE / Key word(s): Conference

06.09.2019 / 10:59
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, 06 September 2019:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences:
 

J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK

- Date: Wednesday, 11 September 2019

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer


Bank of America Merrill Lynch Global Healthcare Conference 2019, London, UK

- Date: Wednesday, 18 September 2019,
           
Presentation: 18 September 2019, 4.25 pm BST

- Venue: London, UK

- Attendee: Werner Lanthaler, Chief Executive Officer


Baader Investment Conference, Munich, Germany

- Date: Monday, 23 September 2019,
           
Presentation: 23 September 2019, 5.15 pm CEST

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer

 

Berenberg and Goldman Sachs Eighth German Corporate Conference, Munich, Germany

- Date: Tuesday, 24 September 2019,
           
Presentation: 24 September 2019, 2.30 pm CEST

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer


Ladenburg Thalmann Healthcare Conference, New York, NY, USA

- Date: Tuesday, 24 September 2019,
           
Presentation: 24 September 2019, 10.30 am EDT

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer


2019 Cantor Global Healthcare Conference, New York, NY, USA

- Date: Wednesday, 02 October 2019,
           
Presentation: 02 October 2019, 3.00 pm EDT

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer

 

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,800 employees provide the highest quality
stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
 

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


Contact Evotec SE:
Gabriele Hansen, VP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com
 



06.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.

GBC-Fokusbox

Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

29. Mai 2020